BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative Colitis

Reuters

02-21

BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative Colitis

Feb 21 (Reuters) - Johnson & Johnson JNJ.N:

TREMFYA® (GUSELKUMAB) SUBCUTANEOUS (SC) INDUCTION DATA SUPPORT POTENTIAL TO BE THE FIRST AND ONLY IN ITS CLASS TO OFFER THE OPTION OF BOTH INTRAVENOUS AND SC INDUCTION THERAPY IN ULCERATIVE COLITIS
J&J: STUDY ACHIEVES PRIMARY AND ALL SECONDARY ENDPOINTS AT WEEK 12
J&J: SAFETY DATA FROM ASTRO STUDY WERE CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF TREMFYA

Source text: ID:nPn7jMWf9a

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2513261444"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2513261444\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2513261444?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-21 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513261444","market":"us","top_or_hot":-1,"title":"BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative Colitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative Colitis</title></head><body><p><span>Feb 21 (Reuters)</span><span> - </span>Johnson &amp; Johnson <span>JNJ.N</span>:</p><ul><li><p>TREMFYA® (GUSELKUMAB) SUBCUTANEOUS (SC) INDUCTION DATA SUPPORT POTENTIAL TO BE THE FIRST AND ONLY IN ITS CLASS TO OFFER THE OPTION OF BOTH INTRAVENOUS AND SC INDUCTION THERAPY IN ULCERATIVE COLITIS</p></li><li><p>J&amp;J: STUDY ACHIEVES PRIMARY AND ALL SECONDARY ENDPOINTS AT WEEK 12</p></li><li><p>J&amp;J: SAFETY DATA FROM ASTRO STUDY WERE CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF TREMFYA</p></li></ul><p>Source text: <span>ID:nPn7jMWf9a</span></p><p>Further company coverage: <span>JNJ.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative Colitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative Colitis\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-02-21 20:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative Colitis</title></head><body><p><span>Feb 21 (Reuters)</span><span> - </span>Johnson &amp; Johnson <span>JNJ.N</span>:</p><ul><li><p>TREMFYA® (GUSELKUMAB) SUBCUTANEOUS (SC) INDUCTION DATA SUPPORT POTENTIAL TO BE THE FIRST AND ONLY IN ITS CLASS TO OFFER THE OPTION OF BOTH INTRAVENOUS AND SC INDUCTION THERAPY IN ULCERATIVE COLITIS</p></li><li><p>J&amp;J: STUDY ACHIEVES PRIMARY AND ALL SECONDARY ENDPOINTS AT WEEK 12</p></li><li><p>J&amp;J: SAFETY DATA FROM ASTRO STUDY WERE CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF TREMFYA</p></li></ul><p>Source text: <span>ID:nPn7jMWf9a</span></p><p>Further company coverage: <span>JNJ.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1674673428.USD","symbol_name":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nFWN3PC04U:1","article_id":"2513261444","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513261444","pubTimestamp":1740139568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative ColitisFeb 21 (Reuters) - Johnson & John","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4550":"红杉资本持仓","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4532":"文艺复兴科技持仓","BK4592":"伊斯兰概念","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4534":"瑞士信贷持仓","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","JNJ":"强生"},"translate_title":"BRIEF-Tremfya皮下（SC）诱导数据支持首次在溃疡性结肠炎中提供静脉和SC诱导治疗选择的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative ColitisFeb 21 (Reuters) - Johnson & Johnson JNJ.N:TREMFYA® (GUSELKUMAB) SUBCUTANEOUS (SC) INDUCTION DATA SUPPORT POTENTIAL TO BE THE FIRST AND ONLY IN ITS CLASS TO OFFER THE OPTION OF BOTH INTRAVENOUS AND SC INDUCTION THERAPY IN ULCERATIVE COLITISJ&J: STUDY ACHIEVES PRIMARY AND ALL SECONDARY ENDPOINTS AT WEEK 12J&J: SAFETY DATA FROM ASTRO STUDY WERE CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF TREMFYASource text: ID:nPn7jMWf9aFurther company coverage: JNJ.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}